Phase 2
Completed N=73
Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
Source: ClinicalTrials.gov NCT00093847 ↗Enrolled (actual)
73
Serious AEs
0.0%
Results posted
Oct 2014
Primary outcomePrimary: Hamilton Depression Rating Scale Remission Rates — 46.1; 17.6 Percentage of Remitters HDRS17
Summary
This study will determine the effectiveness of adding S-adenosyl methionine to antidepressant drug treatment in reducing depressive symptoms in depressed people who have not responded to antidepressants alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hamilton Depression Rating Scale Remission Rates |
46.1; 17.6 | — |
| SECONDARY HDRS17 Responders |
35.8; 11.7 | — |
Eligibility Criteria
Inclusion Criteria
- Major depressive disorder
- Use of an SSRI for at least 6 weeks prior to study entry with partial or no response
Exclusion Criteria
- History of psychosis
- Allergy to SAMe
- Alcohol or drug abuse in the past 3 months prior to study entry
Data sourced from ClinicalTrials.gov (NCT00093847). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.